Last reviewed · How we verify
Ciclesonide (XRP1526)
Ciclesonide is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue.
Ciclesonide is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue. Used for Asthma (maintenance therapy), Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Ciclesonide (XRP1526) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Ciclesonide is a prodrug that is converted to its active metabolite in the lungs, where it binds to glucocorticoid receptors and suppresses inflammatory gene expression. This reduces the production of inflammatory mediators and recruitment of immune cells to the airways, thereby decreasing airway inflammation and improving airflow obstruction in respiratory diseases.
Approved indications
- Asthma (maintenance therapy)
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Palpitations
- Nervousness
- Throat irritation
Key clinical trials
- Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma (PHASE3)
- Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid. (PHASE3)
- Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciclesonide (XRP1526) CI brief — competitive landscape report
- Ciclesonide (XRP1526) updates RSS · CI watch RSS
- Sanofi portfolio CI